Response to comment on “An evidence-based guide to SARS-Cov-2 vaccination of patients on immunotherapies in dermatology.” - 08/07/21
Doi : 10.1016/j.jaad.2021.04.026
Louise M. Gresham, MD a, Barbara Marzario, MD a, Jan Dutz, MD, FRCPC b, Mark G. Kirchhof, MD, PhD, FRCPC a, ⁎ 
a Division of Dermatology, Department of Medicine, University of Ottawa and The Ottawa Hospital, Ontario, Canada
b Department of Dermatology and Skin Sciences, University of British Columbia, Vancouver, Canada
∗Correspondence to: Mark G. Kirchhof, MD, PhD, FRCPC, Division of Dermatology, Department of Medicine, University of Ottawa and The Ottawa Hospital, 737 Parkdale Ave, Ontario K1Y 4E9, CanadaDivision of DermatologyDepartment of MedicineUniversity of Ottawa and The Ottawa Hospital737 Parkdale AveOntarioK1Y 4E9Canada
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2021
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 85 - N° 2
P. e91 - agosto 2021 Ritorno al numero
Articolo precedente
- Comment on “An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology”
- Reinhart Speeckaert, Jo Lambert, Lluís Puig, Marijn Speeckaert, Hilde Lapeere, Sofie De Schepper, Nanja van Geel
- Reply to Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice
- Aizuri Murad, Wilma F. Bergfeld
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.